Tests MAQ-001 safety in adults with advanced cancers
Tests MAQ-001 alone or combined in adults with advanced cancers.
Key facts
- Who runs it
- MabQuest Therapeutics S.A.
- Where
- Lyon, Rennes Cedex, Toulouse Cedex 9, and Villejuif Cedex, FranceSee the 4 sites
- Trial code
- Registry title
- Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancers
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 29 May 2024
- Expected to end
- 13 Feb 2028
- Type of study
- Interventional, 5 groups
- Record updated
- 18 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced cancer where immune checkpoint treatment is an approved option, such as melanoma, lung cancer, kidney cancer, Hodgkin's lymphoma, MSI-high colon cancer, liver cancer or stomach cancer.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced cancer of a type where immune checkpoint blockade is an approved treatment
Where in France
- Centre Leon BerardLyon, FranceTaking people
- Centre De Lutte Contre Le Cancer Eugene MarquisRennes Cedex, FranceTaking people
- Institut Universitaire Du Cancer Toulouse-OncopoleToulouse Cedex 9, FranceTaking people
- Institut Gustave RoussyVillejuif Cedex, FranceTaking people
About the trial
The 5 groups in the trial
- Cohort 1Treatment being tested
1mg/kg of MAQ-001 administered intravenously every 3 weeks
Treatment: MAQ-001
- Cohort 2Treatment being tested
3 mg/kg of MAQ-001 administered intravenously every 3 weeks
Treatment: MAQ-001
- Cohort 3Treatment being tested
10 mg/kg of MAQ-001 administered intravenously every 3 weeks
Treatment: MAQ-001
- Regimen 1Treatment being tested
MAQ-001 at 1 mg/kg in combination with ipilimumab at 3 mg/kg administered intravenously every 3 weeks for the first 4 doses, followed by the maintenance phase of MAQ-001 monotherapy administered intravenously at a dose of 3 mg/kg every 3 weeks (q3W)
Treatment: MAQ-001 and Ipilimumab
- Regimen 2Treatment being tested
MAQ-001 at 3 mg/kg in combination with ipilimumab at 1 mg/kg administered intravenously every 3 weeks for the first 4 doses, followed by the maintenance phase of MAQ-001 monotherapy administered intravenously at a dose of 3 mg/kg every 3 weeks (q3W)
Treatment: MAQ-001 and Ipilimumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Plain-language title
- Tests MAQ-001 safety in adults with advanced cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 March 2026